HOOKIPA Pharma Inc. (HOOK)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HOOKIPA Pharma Inc. (HOOK) trades at $1.06 with AI Score 44/100 (Weak). HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for infectious diseases and cancers using its proprietary arenavirus platform. Market cap: $13.27M, Sector: Healthcare.
Last analyzed: Mar 15, 2026HOOKIPA Pharma Inc. (HOOK) Healthcare & Pipeline Overview
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company leveraging its arenavirus platform to develop immunotherapies for infectious diseases and cancers. With lead candidates in Phase I/II trials targeting HPV16-positive cancers and a Phase II trial for cytomegalovirus, HOOKIPA aims to address unmet needs in oncology and infectious disease within the biotechnology sector.
Investment Thesis
HOOKIPA Pharma Inc. presents a high-risk, high-reward investment opportunity given its clinical-stage pipeline and novel arenavirus platform. Key value drivers include the successful advancement of HB-101 through its Phase II trial and positive data readouts from the HB-201 and HB-202 Phase I/II trials. The collaboration with Gilead Sciences for Hepatitis B Virus (HBV) also represents a potential long-term value driver. However, the company's negative profit margin of -377.0% and limited market capitalization of $0.01 billion highlight the significant financial risks. Upcoming data releases from clinical trials and potential partnership deals are key catalysts to watch. Success in these areas could significantly increase shareholder value, while clinical setbacks or funding challenges pose substantial risks.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion reflects its status as a small-cap biotechnology company.
- Negative P/E ratio of -0.24 indicates the company is currently not profitable.
- Profit margin of -377.0% highlights significant expenses relative to revenue.
- Gross margin of 100.0% suggests strong potential profitability if products are successfully commercialized.
- Beta of 0.82 indicates lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary arenavirus platform for immunotherapy development.
- Clinical-stage pipeline with multiple product candidates.
- Collaboration with Gilead Sciences for HBV vaccine development.
- Experienced management team with expertise in drug development.
Weaknesses
- Limited financial resources and reliance on external funding.
- High risk of clinical trial failures and regulatory setbacks.
- Negative profit margin and limited revenue generation.
- Small market capitalization and potential for stock price volatility.
Catalysts
- Upcoming: Data readout from the Phase II clinical trial of HB-101 in patients awaiting kidney transplantation from CMV-positive donors.
- Upcoming: Data releases from the Phase I/II clinical trials of HB-201 and HB-202 in HPV16-positive cancers.
- Ongoing: Progress in preclinical programs for HB-300 (prostate cancer) and HB-700 (mutated KRAS cancers).
- Ongoing: Advancements in the collaboration with Gilead Sciences for Hepatitis B Virus (HBV) vaccine development.
- Ongoing: Expansion of the arenavirus platform to new therapeutic areas and product candidates.
Risks
- Potential: Clinical trial failures or regulatory setbacks for HB-101, HB-201, and HB-202.
- Potential: Competition from other biotechnology and pharmaceutical companies in the immunotherapy space.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Negative profit margin and limited revenue generation.
- Potential: Patent disputes or intellectual property challenges related to the arenavirus platform.
Growth Opportunities
- Advancement of HB-101: The successful completion of the Phase II clinical trial for HB-101 in patients awaiting kidney transplantation from CMV-positive donors represents a significant growth opportunity. Positive results could lead to regulatory approval and commercialization, addressing a critical need in transplant medicine. The market for CMV therapies is substantial, with a growing population of transplant recipients requiring effective prevention and treatment options. Timeline: Potential market entry within 3-5 years pending trial outcomes and regulatory approvals.
- Development of HB-201 and HB-202: The ongoing Phase I/II clinical trials for HB-201 and HB-202 in HPV16-positive cancers offer a promising growth avenue. Positive clinical data could lead to further development and commercialization in a market with significant unmet needs. HPV16-positive cancers represent a substantial patient population, and effective immunotherapies could capture a significant market share. Timeline: Potential market entry within 5-7 years pending trial outcomes and regulatory approvals.
- Preclinical Programs: HOOKIPA's preclinical programs, including HB-300 for prostate cancer and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer, represent long-term growth opportunities. Successful preclinical development could lead to clinical trials and potential commercialization in these high-prevalence cancer markets. Timeline: Potential market entry within 7-10 years pending preclinical and clinical development.
- Collaboration with Gilead Sciences: The collaboration with Gilead Sciences for Hepatitis B Virus (HBV) vaccine development provides a significant growth opportunity. Leveraging HOOKIPA's arenavirus platform and Gilead's expertise in HBV could lead to the development of novel and effective vaccines. The global market for HBV vaccines is substantial, driven by the need for improved prevention and treatment options. Timeline: Potential market entry within 5-7 years pending research and development progress.
- Expansion of Arenavirus Platform: HOOKIPA's proprietary arenavirus platform offers a versatile platform for developing immunotherapies for various infectious diseases and cancers. Continued innovation and expansion of the platform could lead to the development of new product candidates and partnerships, driving long-term growth. The platform's ability to stimulate strong immune responses positions it favorably in the immunotherapy market. Timeline: Ongoing, with continuous development and potential for new product candidates.
Opportunities
- Successful completion of clinical trials and regulatory approvals.
- Expansion of the arenavirus platform to new therapeutic areas.
- Strategic partnerships and collaborations with larger pharmaceutical companies.
- Growing demand for immunotherapies in oncology and infectious disease.
Threats
- Competition from other biotechnology and pharmaceutical companies.
- Changes in regulatory requirements and healthcare policies.
- Economic downturns and market volatility.
- Patent disputes and intellectual property challenges.
Competitive Advantages
- Proprietary Arenavirus Platform: HOOKIPA's patented arenavirus platform provides a unique and differentiated approach to immunotherapy development.
- Clinical-Stage Pipeline: The company's pipeline of clinical-stage product candidates provides a potential first-mover advantage in specific therapeutic areas.
- Strategic Collaborations: Partnerships with established pharmaceutical companies, such as Gilead Sciences, provide access to resources and expertise.
- Experienced Management Team: HOOKIPA's management team has a proven track record in drug development and commercialization.
About HOOK
HOOKIPA Pharma Inc., founded in 2011 and headquartered in New York City, is a biopharmaceutical company focused on developing immunotherapies based on its proprietary arenavirus platform. The company's innovative approach aims to harness the power of the immune system to fight infectious diseases and cancers. HOOKIPA's lead infectious disease product candidate, HB-101, is currently in a Phase II clinical trial for patients awaiting kidney transplantation from cytomegalovirus (CMV)-positive donors. In oncology, the company's lead product candidates, HB-201 and HB-202, are in Phase I/II clinical trials for the treatment of human papillomavirus 16 (HPV16)-positive cancers. Furthermore, HOOKIPA has preclinical programs, including HB-300 for prostate cancer and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA also has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company’s focus on innovative immunotherapy and strategic collaborations positions it within the competitive biotechnology landscape.
What They Do
- Develops immunotherapies for infectious diseases and cancers.
- Utilizes a proprietary arenavirus platform to stimulate the immune system.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Focuses on unmet medical needs in oncology and infectious disease.
- Collaborates with other pharmaceutical companies to expand its research and development efforts.
- Targets diseases such as cytomegalovirus (CMV) and human papillomavirus 16 (HPV16)-positive cancers.
- Develops preclinical programs for prostate cancer and mutated KRAS cancers.
Business Model
- Develops and patents novel immunotherapies based on its arenavirus platform.
- Out-licenses or co-develops its product candidates with larger pharmaceutical companies.
- Generates revenue through research grants, collaboration agreements, and potential future product sales.
- Focuses on clinical development and regulatory approval of its product candidates.
Industry Context
HOOKIPA Pharma Inc. operates in the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The industry is driven by innovation and the development of new therapies for unmet medical needs. The global biotechnology market is projected to reach trillions of dollars by 2030, fueled by advancements in genomics, proteomics, and personalized medicine. HOOKIPA competes with companies like IMUC, CHMMF, DVHGF, HMTXF, and LIANY, all vying for market share in the immunotherapy and vaccine space.
Key Customers
- Patients suffering from infectious diseases, such as cytomegalovirus (CMV).
- Patients diagnosed with HPV16-positive cancers.
- Pharmaceutical companies seeking to collaborate on immunotherapy development.
- Healthcare providers who prescribe and administer immunotherapies.
Financials
Chart & Info
HOOKIPA Pharma Inc. (HOOK) stock price: $1.06 (+0.00, +0.00%)
Latest News
-
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
benzinga · Dec 21, 2023
-
Earnings Scheduled For August 10, 2023
benzinga · Aug 10, 2023
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Jan 17, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Dec 12, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HOOK.
Price Targets
Wall Street price target analysis for HOOK.
MoonshotScore
What does this score mean?
The MoonshotScore rates HOOK's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Earnings Scheduled For August 10, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Stocks That Hit 52-Week Lows On Monday
Leadership: Malte Peters
CEO
Malte Peters serves as the CEO of HOOKIPA Pharma Inc. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining HOOKIPA, he held leadership positions at several prominent companies, focusing on drug development, clinical research, and commercialization. Peters has a strong scientific background and a proven track record of driving innovation and growth in the healthcare sector. His expertise spans various therapeutic areas, including oncology and infectious diseases.
Track Record: Under Malte Peters' leadership, HOOKIPA Pharma Inc. has advanced its clinical-stage pipeline and secured strategic collaborations, including the partnership with Gilead Sciences. He has overseen the progression of HB-101, HB-201, and HB-202 through clinical trials, and has guided the company's research and development efforts. Peters has focused on expanding the applications of HOOKIPA's arenavirus platform and building a strong foundation for future growth.
HOOK OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that HOOKIPA Pharma Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and requires careful due diligence from investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and regulatory oversight.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for price volatility and manipulation.
- Increased risk of fraud or misrepresentation.
- Higher risk of delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Collaboration with Gilead Sciences suggests some level of institutional validation.
- Focus on clinical trials and regulatory approvals indicates a commitment to scientific rigor.
- Experienced management team with expertise in drug development.
- Development of a proprietary arenavirus platform suggests innovation.
HOOKIPA Pharma Inc. Stock: Key Questions Answered
What does HOOKIPA Pharma Inc. do?
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company that develops immunotherapies for infectious diseases and cancers. The company's proprietary arenavirus platform is designed to stimulate the immune system to fight these diseases. Its lead product candidates include HB-101 for cytomegalovirus (CMV) and HB-201/HB-202 for human papillomavirus 16 (HPV16)-positive cancers. HOOKIPA also has preclinical programs targeting prostate cancer and mutated KRAS cancers. The company collaborates with Gilead Sciences for Hepatitis B Virus (HBV) vaccine development.
What do analysts say about HOOK stock?
Analyst coverage of HOOKIPA Pharma Inc. is limited, reflecting its small market capitalization and clinical-stage status. Key valuation metrics include its potential for future revenue generation based on the success of its clinical trials and partnerships. Growth considerations center on the advancement of its product candidates through clinical development and regulatory approval. Analyst consensus is pending updated stock data, but investors should closely monitor clinical trial results and partnership developments as key drivers of stock performance. No buy or sell recommendations are available at this time.
What are the main risks for HOOK?
The main risks for HOOKIPA Pharma Inc. include the inherent uncertainties of clinical-stage drug development, such as clinical trial failures and regulatory setbacks. The company also faces competition from other biotechnology and pharmaceutical companies in the immunotherapy space. Financial risks include limited financial resources, reliance on external funding, and a negative profit margin. Additionally, there are potential risks related to patent disputes, intellectual property challenges, and market volatility, given its OTC listing.
What are the key factors to evaluate for HOOK?
HOOKIPA Pharma Inc. (HOOK) currently holds an AI score of 44/100, indicating low score. Key strength: Proprietary arenavirus platform for immunotherapy development.. Primary risk to monitor: Potential: Clinical trial failures or regulatory setbacks for HB-101, HB-201, and HB-202.. This is not financial advice.
How frequently does HOOK data refresh on this page?
HOOK prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HOOK's recent stock price performance?
Recent price movement in HOOKIPA Pharma Inc. (HOOK) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary arenavirus platform for immunotherapy development.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HOOK overvalued or undervalued right now?
Determining whether HOOKIPA Pharma Inc. (HOOK) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HOOK?
Before investing in HOOKIPA Pharma Inc. (HOOK), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than major exchanges.
- Clinical trial outcomes are inherently uncertain and can impact future results.